Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders
Advancing ABX-002, a highly potent, selective and centrally active thyromimetic, into Phase 2 clinical trials for patients with major depressive disorder and bipolar disorder depression Advancing neuroimmunology candidate, ABX-101, a first-in-class, centrally penetrant S1P modulator,…